ClinicalTrials.gg
WithdrawnNCT04281524Updated Mar 25, 2020

A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line

A Phase 1/2 interventional study of CSL312 and Placebo in PICC-associated Thrombosis, sponsored by CSL Behring. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-25.

Sponsored by CSL Behring (part of CSL Limited) · Phase 1/2, Interventional, and Prevention

Why this study was withdrawn
Business decision non-safety related.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Peripherally Inserted Central Catheters (PICCs) are commonly used in patients with cancer to administer chemotherapy and supportive care medication. However, PICCs and other medical devices that come into contact with blood increase the risk of blood clots (thrombosis) inside the blood vessels. Conventional blood thinners (anticoagulants) may reduce the risk of thrombosis but they also increase the risk of bleeding. CSL312, a monoclonal antibody that inhibits the activated blood clotting factor 12 (FXIIa) will be assessed for its potential to prevent thrombus formation in subjects with cancer at risk of PICC-associated thrombosis.

02

Conditions studied

  • PICC-associated Thrombosis
03

In context

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older at the time of providing written
  • Diagnosis of that requires placement of a PICC within the next 3 weeks for administration of chemotherapy (PICC anticipated to be required for at least 1 month)
  • (ECOG) performance status of 0, 1, or 2 [Oken et al, 1982], and investigator's expectation that performance status will remain 0, 1, or 2 for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Active bleeding or with a current coagulopathy (eg, [INR] > 1.5) or clinically significant risk for bleeding (eg, recent intracranial hemorrhage or bleeding peptic ulcer within the last 4 weeks)
  • History of venous thrombosis, myocardial infarction or cerebrovascular event within 3 months, or a prothrombotic disorder (eg, antithrombin III, protein C or S deficiency)
  • less than study duration (110 days)
  • count of \< 20 × 109/L on the day of dose 1 (Day 1) or within 7 days before first dosing
  • Estimated (eGFR) \< 30 mL/min/1.73 m2
  • Treatment with antiplatelet or anticoagulant medication, including thrombosis prophylaxis, within 10 days prior to insertion of the PICC
  • Chemotherapy regimen that would be expected to drop the platelet count to \< 20 × 109/L
  • Chemotherapy regimen with heparin mixed into IV bags (eg, dalteparin 2500 IU/day)
  • Difficult IV access that would prevent infusion of the IP
  • In situ central venous catheter (CVC) or PICC in the 3 months before the Screening Visit. The study PICC must be inserted in the contralateral side, which must be PICC / CVC naïve
  • Undergoing dialysis or have another inserted intravascular foreign surface device
  • Serum (AST) and serum alanine aminotransferase (ALT) ≥ 4 ×
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    CSL312 Cohort 1 (Dose 1)

    CSL312 administered as IV infusion

    Drug: CSL312

  • Experimental
    CSL312 Cohort 2 (Dose 2)

    CSL312 administered as IV infusion

    Drug: CSL312

  • Experimental
    CSL312 Cohort 3 (Dose 3)

    CSL312 administered as IV infusion

    Drug: CSL312

  • Experimental
    CSL312 Cohort 4 (Dose 4)

    CSL312 administered as IV infusion

    Drug: CSL312

  • Placebo comparator
    Placebo

    Placebo administered as IV infusion

    Drug: Placebo

Interventions

  • DrugCSL312

    CSL312 administered as an IV infusion

    Also known as: Garadacimab

  • DrugPlacebo

    Solution of 70% 0.9% saline / 30% CSL312 diluent

06

What researchers measure

Primary outcomes

  1. Number of subjects with PICC-associated thrombosis

    PICC-associated thrombosis which can be either: 1. Asymptomatic PICC associated thrombosis detected by Duplex ultrasound (DUS) or venography at Day 15 or Day 29 after PICC insertion or 2. Symptomatic PICC associated thrombosis up to Day 29 after PICC insertion, suspected clinically due to symptoms of the upper limb or neck, and objectively confirmed by DUS or venography

    Time frame: Up to 29 days after PICC insertion

  2. Percent of subjects with PICC-associated thrombosis

    PICC-associated thrombosis which can be either: 1. Asymptomatic PICC associated thrombosis detected by Duplex ultrasound (DUS) or venography at Day 15 or Day 29 after PICC insertion or 2. Symptomatic PICC associated thrombosis up to Day 29 after PICC insertion, suspected clinically due to symptoms of the upper limb or neck, and objectively confirmed by DUS or venography

    Time frame: Up to 29 days after PICC insertion

Secondary outcomes

  1. Overall percentage of subjects with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Up to 110 days after first dose of CSL312

  2. Percent of subjects with related TEAEs

    Time frame: Up to 110 days after first dose of CSL312

  3. Percent of subjects with TEAEs by severity

    Time frame: Up to 110 days after first dose of CSL312

  4. Number of subjects treated with CSL312 with detectable antibodies to CSL312

    Time frame: Up to 110 days after first dose of CSL312

  5. Percent of subjects treated with CSL312 with detectable antibodies to CSL312

    Time frame: Up to 110 days after first dose of CSL312

  6. Maximum plasma concentration (Cmax) of CSL312

    Time frame: Up to 110 days after first dose of CSL312

  7. Area under the concentration-time curve (AUC0-t) of CSL312

    Time frame: Up to 110 days after first dose of CSL312

  8. Time of maximum plasma concentration (Tmax) of CSL312

    Time frame: Up to 110 days after first dose of CSL312

  9. Terminal elimination half-life (T1/2) of CSL312

    Time frame: Up to 110 days after first dose of CSL312

  10. Total systemic clearance (CLtot) of CSL312

    Time frame: Up to 110 days after first dose of CSL312

  11. Volume of distribution during the elimination phase (Vz) of CSL312

    Time frame: Up to 110 days after first dose of CSL312

  12. Accumulation Ratio (AR) of CSL312

    Time frame: Up to 110 days after first dose of CSL312

  13. Number of subjects with thrombosis-associated catheter occlusion

    Time frame: Up to 29 days after first dose of CSL312

  14. Percent of subjects with thrombosis-associated catheter occlusion

    Time frame: Up to 29 days after first dose of CSL312

  15. Number of subjects with PICC removal or replacement

    Time frame: Up to 29 days after first dose of CSL312

  16. Percent of subjects with PICC removal or replacement

    Time frame: Up to 29 days after first dose of CSL312

  17. Number of subjects with central line-associated blood stream infections (CLABSI)

    Time frame: Up to 29 days after first dose of CSL312

  18. Percent of subjects with CLABSI

    Time frame: Up to 29 days after first dose of CSL312

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2020; primary completion for Aug 2021, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2020
First posted
Feb 24, 2020
StartEst.
Mar 2020
Primary completionEst.
Aug 2021
CompletionEst.
Oct 2021
Last update
Mar 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04281524
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Feb 24, 2020
Start date
Mar 2020 (estimated)
Primary completion
Aug 2021 (estimated)
Completion
Oct 2021 (estimated)
Last update
Mar 25, 2020

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garadacimab

Start the discussion